In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice

Stem Cells
K KabayaH Miyazaki

Abstract

The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG-rHuMGDF was more potent in producing platelets and the dose-response curve was steeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG-rHuMGDF caused a dose-dependent increase in peripheral platelet counts with a peak on day 8. There was a dose-dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 micrograms/kg. Intermediate doses of PEG-rHuMGDF (1.111 to 10 micrograms/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG-rHuMGDF (30 to 270 micrograms/kg/day) induced a dose-dependent increase in mean platelet volume. There was a dose-dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG-rHuMGDF administration. White blood cell counts were unchanged by PEG-rHuMGDF treatment. Marrow megakaryocyte size enlarged to 1.5-fold and the number of marrow megakaryocytes increased to sixfold by co...Continue Reading

References

Aug 1, 1968·The American Journal of Physiology·P A ChervenickM M Wintrobe
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·K KaushanskyC Lofton-Day
Jun 9, 1995·Gene·K OgamiH Miyazaki
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·D J KuterR D Rosenberg
Jun 16, 1994·Nature·F WendlingW Vainchenker
Jul 1, 1995·Journal of Biochemistry·T KatoE Maeda

❮ Previous
Next ❯

Citations

Apr 23, 2002·Journal of Cellular Biochemistry·Ying ZhangKatya Ravid
Aug 30, 2008·Science in China. Series C, Life Sciences·B LuP Huang
Mar 31, 1999·International Journal of Radiation Oncology, Biology, Physics·M A MouthonG Wagemaker
May 5, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·H AkahoriH Miyazaki
Sep 22, 2007·Science·Tobias JuntUlrich H von Andrian
May 27, 2010·The Tohoku Journal of Experimental Medicine·Chikashi NakanishiSusumu Satomi
Feb 5, 2008·Experimental Hematology·Petr BartunekMichal Dvorak
Nov 8, 2006·European Journal of Haematology·Ken-ichi SuzukiTatsutoshi Nakahata
Nov 11, 2015·The Journal of Experimental Medicine·Ayako Nakamura-IshizuToshio Suda
Dec 3, 2014·Biochemical and Biophysical Research Communications·Ayako Nakamura-IshizuToshio Suda
Apr 20, 2002·Blood·Keita KiritoNorio Komatsu
Dec 31, 1997·Molecular and Cellular Biology·J M ZimmetK Ravid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.